Search Results
Jan 16, 2026, 08:00 ET SUNSTONE HOTEL INVESTORS SCHEDULES FOURTH QUARTER AND FULL YEAR 2025 EARNINGS RELEASE AND CONFERENCE CALL
Calif., Jan. 16, 2026 /PRNewswire/ -- Sunstone Hotel Investors, Inc. (the "Company" or "Sunstone") (NYSE: SHO) announced that it will report financial results for the fourth quarter and full year 2025 on Friday, February 27, 2026, before the market opens. Management
More news about: Sunstone Hotel Investors, Inc.
Jan 06, 2026, 08:00 ET Novo Nordisk unveils the inaugural State of Weight and Health Report™, offering new insights that shed light on America's obesity epidemic
[email protected] Sho Togo Tullin (Global)+45 3079 1471
More news about: NOVO NORDISK INC.
Jan 05, 2026, 08:00 ET Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
[email protected] Christoffer Sho Togo Tullin (Global) +45 3079 1471
More news about: NOVO NORDISK INC.
Dec 22, 2025, 18:03 ET FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults
Christoffer Sho Togo Tullin (Global)+45 3079
More news about: NOVO NORDISK INC.
Dec 21, 2025, 20:08 ET TOMY將推出第12彈「新春TOMICA」系列 匯聚招福吉祥圖案
Fuku Fuku TOMICA」、2014年「Kouhaku Fuku Fuku TOMICA」、2015年「Kabukimono TOMICA」、2016 年「TOMICA Mukashibanashi」、2017年「TOMICA Hyakunin Isshu」、2018 年「TOMICA Sho」、2020 年「Manpuku TOMICA」、2021 年「Fukumono TOMICA」、2022 年「Fukutoku TOMICA」、2023 年「Fukutomi TOMICA」及 2024年「Hyakufuku TOMICA」，本彈「福舞TOMICA」為該系列第12彈作品。關於
More news about: TOMY Company, Ltd.
Dec 18, 2025, 08:00 ET Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
[email protected] Christoffer Sho Togo Tullin (Global) +45 3079 [email protected]
More news about: NOVO NORDISK INC.
Dec 18, 2025, 08:00 ET Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
[email protected] Christoffer Sho Togo Tullin (Global) +45 3079 [email protected]
More news about: NOVO NORDISK INC.
Dec 04, 2025, 16:30 ET Xenia Hotels & Resorts Provides Business Update
its share repurchase authorization as of December 4th. Referenced lodging REIT peers include DRH, HST, PK, PEB, and SHO and is based upon publicly available information.Same-Property rooms revenues growth rate of +3.4%, Same-Property non-rooms revenues growth
More news about: Xenia Hotels & Resorts, Inc.
Nov 26, 2025, 08:00 ET Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
[email protected] Sho Togo Tullin+45 3079 1471
More news about: NOVO NORDISK INC.
Nov 20, 2025, 13:17 ET Jobley to Exhibit at the Largest Dental Conference in the U.S.
"We're thrilled to bring Jobley's results-driven, tailored hiring solution to one of the nation's most prominent dental gatherings," said Sho Kajino, who leads business operations for Jobley. "At GNYDM 2025, we look forward to highlighting how our model helps dental providers overcome persistent
More news about: Medley US, Inc.
Nov 17, 2025, 07:30 ET SUNSTONE HOTEL INVESTORS ANNOUNCES EXPANSION OF BOARD OF DIRECTORS
Calif., Nov. 17, 2025 /PRNewswire/ -- Sunstone Hotel Investors, Inc. (the "Company" or "Sunstone") (NYSE: SHO) today announced the appointment of Michael Barnello to the Company's Board of Directors. The appointment is effective as of November 15, 2025 and Sunstone
More news about: Sunstone Hotel Investors, Inc.
Nov 10, 2025, 08:46 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
Christoffer Sho Togo Tullin
More news about: NOVO NORDISK INC.
Nov 10, 2025, 08:45 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
Christoffer Sho Togo Tullin
More news about: NOVO NORDISK INC.
Nov 07, 2025, 07:30 ET SUNSTONE HOTEL INVESTORS REPORTS RESULTS FOR THIRD QUARTER 2025
Calif., Nov. 7, 2025 /PRNewswire/ -- Sunstone Hotel Investors, Inc. (the "Company" or "Sunstone") (NYSE: SHO) today announced results for the third quarter ended September 30, 2025. Third Quarter 2025 Operational
More news about: Sunstone Hotel Investors, Inc.
Nov 06, 2025, 14:30 ET Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
Christoffer Sho Togo Tullin +45 3079 1471
More news about: NOVO NORDISK INC.
Nov 06, 2025, 14:30 ET Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
Christoffer Sho Togo Tullin +45 3079 1471
More news about: NOVO NORDISK INC.
Nov 05, 2025, 08:15 ET Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
Christoffer Sho Togo Tullin +45 3079 1471
More news about: NOVO NORDISK INC.
Nov 05, 2025, 08:15 ET Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
Christoffer Sho Togo Tullin +45 3079 1471
More news about: NOVO NORDISK INC.
Oct 28, 2025, 08:00 ET Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting
Christoffer Sho Togo Tullin +45 3079 1471
More news about: NOVO NORDISK INC.
Oct 28, 2025, 08:00 ET Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting
Christoffer Sho Togo Tullin +45 3079 1471
More news about: NOVO NORDISK INC.
Oct 27, 2025, 16:06 ET Welltower Announces $23 Billion of Transactions and Intensified Focus on Seniors Housing to Amplify Long-Term Growth Profile
1Estimated seniors housing exposure incorporates transactions closed or under contract to close as of October 27, 2025, as well as SHO incremental in-place NOI detailed on Welltower's "Path to Recovery" slide on page 27 of the October 27, 2025 Business Update. See "Supplemental Financial
More news about: Welltower Inc.
Oct 27, 2025, 16:05 ET Welltower Reports Third Quarter 2025 Results
portfolio year-over-year same store NOI ("SSNOI") growth of 14.5%, driven by SSNOI growth in our Seniors Housing Operating ("SHO") portfolio of 20.3% SHO portfolio year-over-year same store margin expanded by 260 basis points ("bps") driven by increased same store revenue of
More news about: Welltower Inc.
Oct 23, 2025, 09:00 ET JW MARRIOTT DEBUTS IN TOKYO, MARKING BOLD EXPANSION IN JAPAN WITH THE UNVEILING OF JW MARRIOTT HOTEL TOKYO
Hill. These vistas are complemented by traditional Kamakura-bori inspired artworks that capture dramatic cloudscapes in muted tones. Photographic art by Sho Makishima, employing soft colors and delicate light trails, depicts the ever-changing beauty of nature and serves as a poetic metaphor for the Takanawa
More news about: Marriott International, Inc.
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
Christoffer Sho Togo Tullin (Global)+45 3079 1471
More news about: NOVO NORDISK INC.
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
Christoffer Sho Togo Tullin (Global)+45 3079 1471
More news about: NOVO NORDISK INC.